ClinicalThought
View More
How do you treat patients with newly diagnosed CLL in the era of new agents? In this commentary, Dr. Flinn discusses emerging frontline combination regimens for the treatment of CLL.
Ian W. Flinn, MD, PhD
Released: May 3, 2019
Are you aware of some of the latest clinical data in CLL? In this commentary, I will discuss 3 key studies on venetoclax, acalabrutinib, and lisocabtagene maraleucel in CLL that were presented at ASCO 2019.
Susan M. O'Brien, MD
Released: June 27, 2019
Farrukh Awan, MD, MS, discusses recent advances and clinical data in CLL that led to an updated online treatment decision support tool for CLL from Clinical Care Options.
Farrukh T. Awan, MD
Released: November 13, 2019
Acalabrutinib is now approved for treating patients with CLL. Are you ready to incorporate it into your practice?
Nicole Lamanna, MD
Released: January 10, 2020
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.